Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
By LabMedica International staff writers Posted on 07 Feb 2024 |
Sysmex Corporation (Kobe, Japan) has entered into a strategic alliance agreement with CellaVision (Lund, Sweden) to advance hematology solutions. This collaboration aims to expand Sysmex's product range, including the development of cutting-edge cell morphology analyzers. Together, Sysmex and CellaVision will strive to improve the efficiency and standardization of testing workflows in hematology, enhance the accuracy of cell morphology classification, and provide valuable support in diagnostic processes.
The partnership between Sysmex and CellaVision has spanned 20 years, focusing on hematology, which involves the analysis of blood cells such as red and white blood cells in terms of their count, types, and sizes. This collaboration began in 2001 when Sysmex entered a sales alliance for CellaVision’s cell morphology analyzers. In 2013, Sysmex introduced the DI-60 Automated Digital Cell Morphology Analyzer, a product of its collaboration with CellaVision. This system, when integrated with Sysmex’s hematology analyzers, automates up to the cell morphology analysis stage, significantly streamlining and standardizing testing workflows in clinical laboratories worldwide.
The renewed partnership between the two companies aims to enhance their product offerings, particularly in next-generation cell morphology analyzers. They have agreed to extend their collaborative efforts to advance hematology solutions and maintain their agreement until 2038. Leveraging a stable, long-term collaborative framework, Sysmex plans to utilize its expertise in optimizing testing workflows in hematology, while CellaVision will contribute its advanced digital imaging and analysis technologies. These joint efforts are intended to further improve efficiency and standardization in testing workflows and increase clinical value by providing more precise cell morphology classification to aid in diagnoses.
“We are pleased to expand our alliance with CellaVision since 2013,” said Takashi Ono, Member of the Managing Board and Senior Executive Officer, Managing Director at Sysmex Corporation. “This alliance enables us to further enhance our leadership position in hematology worldwide. We will collaborate wider and deeper to increase value to our customers by portfolio expansion in digital cell morphology.”
"This alliance marks an important milestone in our joint mission to elevate healthcare and evolve microscopy together for a better healthcare journey,” said Simon Østergaard, President & CEO, CellaVision AB. “We are delighted to further strengthen our ties with Sysmex to continue the global adoption of advanced digital cell morphology solutions integrated with the leading cell counter offerings of Sysmex.”
Related Links:
Sysmex Corporation
CellaVision
Latest Industry News
- Danaher and Johns Hopkins University Collaborate to Improve Neurological Diagnosis
- Beckman Coulter and MeMed Expand Host Immune Response Diagnostics Partnership
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance
- Roche Acquires LumiraDx's Point of Care Technology for USD 295 Million